EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Energenesis Biomedical Co. Ltd. (6657) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Energenesis Biomedical Co. Ltd. TWD 7.85, price TWD 32.80, upside -76.1%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW

EB Thin data Sep 24, 2026

Energenesis Biomedical Co. Ltd.

6657 · TW

Weakest SetupStrongly overvalued and low quality.

!Fair value 7.85 TWD · Strongly overvalued (−76%)
!Quality 24/100
!Weak Growth (revenue 5y +1.6 %/yr)
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
Watch Energenesis Biomedical Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

96.00 TWD 29.40 TWD Fair Value 7.85 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 29.40 TWD – 96.00 TWD · fair‑value band 5.18 TWD – 9.81 TWD · the 32.80 TWD price screens above the 7.85 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Energenesis Biomedical Co. in your weekly email

Every Wednesday you see whether Energenesis Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan.

Show more

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, including western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.

Stock analysis

Energenesis Biomedical Co. Ltd. (6657) currently trades at 32.80 TWD, while our model-based Fair Value estimate is 7.85 TWD, implying the stock looks roughly 318.1% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 5.18 TWD (bear) to 9.81 TWD (bull), the price of 32.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Energenesis Biomedical Co. Ltd. reported revenue of 7.7M TWD in FY2025 versus 7.5M TWD in FY2021, a compound +0.6%/yr. Reported net income was −258M TWD in FY2025.

Key figures

Market cap 2.9B TWD (≈ $91.4M) · EPS (TTM) −2.92 TWD · Return on equity −21.6% · Return on assets (EBIT) −29.8% · Operating margin −3,652% · Revenue (TTM) 7.9M TWD · Revenue growth (YoY) +14.7% · Free cash flow −225M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 44% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −76%, 6657 screens richer than that median.

Fair Value models

Bear 5.18 TWD Fair Value 7.85 TWD Bull 9.81 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 5.10 TWD 6.83 TWD 10.20 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 5.10 TWD 6.83 TWD 10.20 TWD 51

Open the full fair value analysis →

Notify me when 6657 reaches fair value

Put 6657 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 30 · Market factors (momentum, volatility) 28

Profitability 0
Margins and returns on capital today
Quality Growth 42
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 19
Disciplined investing over empire-building
Low Volatility 67
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 3/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,823.6% (2020) → −3,587.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6657 screens 318% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Energenesis Biomedical Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −76% · Bottom 25%
Profitability
Return on assets −14% · Below median
Growth and dividend
Revenue growth 15% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.10× · Cheapest 25%
P/S (TTM) 11.64× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)74 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Energenesis Biomedical Co. Ltd. · Fair Value
7.85 TWD −318%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Energenesis Biomedical Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6657

Frequently asked questions

Is Energenesis Biomedical Co. Ltd. (6657) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 7.85 TWD versus a price of 32.80 TWD, about −76% upside (overvalued).
What is the fair value of 6657?
Our model-based fair value for Energenesis Biomedical Co. Ltd. is 7.85 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 32.80 TWD.
What is the quality score of 6657?
Energenesis Biomedical Co. Ltd. has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Energenesis Biomedical Co. Ltd. (6657)?
Our model-based price target is the fair value of 7.85 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 5.18 TWD, optimistic scenario 9.81 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Energenesis Biomedical Co. Ltd. stock forecast for 2026?
Our models put fair value at 7.85 TWD, about −76% upside versus a price of 32.80 TWD (overvalued). Cautious scenario 5.18 TWD, optimistic scenario 9.81 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Energenesis Biomedical Co. Ltd. (6657)?
Energenesis Biomedical Co. Ltd. reported trailing-twelve-month revenue of about 7.9M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Energenesis Biomedical Co. Ltd. (6657)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Energenesis Biomedical Co. Ltd. it is 7.85 TWD per share (as of Sep 24, 2026), against a price of 32.80 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Energenesis Biomedical Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6657 trades above its calculated fair value: price 32.80 TWD, fair value 7.85 TWD, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6657?
No. The price is what the market pays today (32.80 TWD); the fair value is what the company's own numbers justify (7.85 TWD). For Energenesis Biomedical Co. Ltd. the two are 24.95 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Energenesis Biomedical Co. Ltd. worth?
The market values Energenesis Biomedical Co. Ltd. at about 2.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 32.80 TWD; our models calculate a fair value of 7.85 TWD per share.
What do the bullish and bearish scenarios say about 6657?
Our models span a range for Energenesis Biomedical Co. Ltd.: cautious scenario 5.18 TWD, base 7.85 TWD, optimistic 9.81 TWD per share (as of Sep 24, 2026, price 32.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Energenesis Biomedical Co. Ltd. (6657)?
Balance-sheet figures for Energenesis Biomedical Co. Ltd. (as of Sep 24, 2026): return on equity −21.6%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 6657 from its 52-week high?
Energenesis Biomedical Co. Ltd. trades at 32.80 TWD, about 44% below its 52-week high of 58.60 TWD and 12% above the low of 29.40 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 7.85 TWD is for.
Which stocks are comparable to Energenesis Biomedical Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Energenesis Biomedical Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 32.80 TWD, calculated fair value 7.85 TWD (−76%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6657 calculated?
We run Energenesis Biomedical Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7.85 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Energenesis Biomedical Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Energenesis Biomedical Co. Ltd. (6657)?
The closing price on Sep 24, 2026 was 32.80 TWD. Our model-based fair value is 7.85 TWD, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Energenesis Biomedical Co. Ltd. right now?
The price sits above even our optimistic bull case (9.81 TWD). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (5.18 TWD to 9.81 TWD) leaves room in how you read the outcome.

Key figures of Energenesis Biomedical Co. Ltd.

How large is the market capitalisation of Energenesis Biomedical Co. Ltd. (6657)?
The market capitalisation of Energenesis Biomedical Co. Ltd. is 2.9B TWD (≈ $91.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Energenesis Biomedical Co. Ltd. (6657)?
Earnings per share at Energenesis Biomedical Co. Ltd. are −2.92 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Energenesis Biomedical Co. Ltd. (6657)?
The return on equity (ROE) of Energenesis Biomedical Co. Ltd. is −21.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Energenesis Biomedical Co. Ltd. (6657)?
On an EBIT basis the return on assets of Energenesis Biomedical Co. Ltd. is −29.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Energenesis Biomedical Co. Ltd. (6657)?
The operating margin of Energenesis Biomedical Co. Ltd. is −3,652% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Energenesis Biomedical Co. Ltd. (6657)?
Revenue at Energenesis Biomedical Co. Ltd. is growing +14.7% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Energenesis Biomedical Co. Ltd. (6657) generate?
The free cash flow of Energenesis Biomedical Co. Ltd. is −225M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Energenesis Biomedical Co. Ltd. (6657) hold?
Energenesis Biomedical Co. Ltd. holds more cash than debt, 658M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Energenesis Biomedical Co. Ltd. in the live analysis

One click puts Energenesis Biomedical Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.